Erythropoietin use for diabetic ulcers

NewsBot · Dec 19, 2013

Members do not see these Ads. Sign Up.
Erythropoietin, a novel repurposed drug: An innovative treatment for wound healing in patients with diabetes mellitus
Saher Hamed et al
Wound Repair and Regeneration; Early View

Developing a new drug is expensive: the cost of going from bench to bedside is about $US1 billion. Therefore, the repurposing of an approved drug is potentially rewarding because it expands the drug's existing therapeutic profile and preempts additional development costs. As the safety profile of a repurposed drug is already well known, any new investigations could then focus on its efficacy and other therapeutic benefits. Recombinant erythropoietin (EPO) is a potential candidate for repurposing because the results of numerous studies have shown that systemic and topical EPO is therapeutically beneficial when it is administered to healthy and diabetic animals with acute and chronic skin wounds and burns. Moreover, the molecular mechanisms of EPO's actions have been elucidated: EPO acts on those nonhematopoietic cells which are involved in the innate immune response where it promotes cellular proliferation and differentiation, exerts its cytoprotective actions, and inhibits apoptosis. In this review, the mechanism of EPO's action in skin wound healing is reviewed, and its potential for treating acute and chronic skin wounds and stimulating tissue regeneration in diabetic patients is discussed.
Click to expand...

Admin2 · Dec 19, 2013

Related Threads:
Statins and diabetic foot ulcers
ACE Inhibitors and Diabetic Foot Ulcers

NewsBot · Sep 25, 2016

Erythropoietin-activated mesenchymal stem cells promote healing ulcers by improving microenvironment.
Lu H et al
J Surg Res. 2016 Oct;205(2):464-473. doi: 10.1016/j.jss.2016.06.086

BACKGROUND:
Mesenchymal stem cell (MSC) transplantation is an effective treatment therapy for ischemic ulcers. However, in high-glucose microenvironment, the original inflammation-inhibiting function of MSCs leads to turns into secreting large amounts of inflammatory mediators, such as tumor necrosis factor alpha, for example, which decreases their capacity and becomes poor quality stem cells over inflammation cells for diabetic foot ulcers repair in the healing of diabetic foot ulcers. Erythropoietin (EPO) is an anti-inflammatory, proangiogenic cytokine. It is unclear whether EPO-activated MSCs with biomaterials can promote the effective healing of diabetic foot ulcers.
METHODS:
Cultivated MSCs in MSC-L, MSC-H, EPO-G, Akt-G, and mTOR-G, then separated the supernatant-conditioned medium of these groups to stimulate human umbilical vein endothelial cells on proliferation and migration experiments; a new type of biomaterial planted with the EPO-activated MSCs was applied to the diabetic foot ulcers of the C57 mice.
RESULTS:
In vitro experiments showed that EPO could stimulate MSCs to secrete vascular endothelial growth factor in high-glucose microenvironment. More importantly, EPO could reduce the damage to MSCs by high-glucose microenvironment, promote their proliferation and migration functions, and inhibit the high-glucose-induced MSCs from secreting the inflammatory mediator tumor necrosis factor alpha. In vivo experiments showed greater angiogenesis in EPO-MSC group than in control group, ulcer healing in EPO-MSC group was significantly better than that in control group, and MSCs partially differentiated into endothelial cells. EPO-activated MSCs could inhibit the monocyte invasion of localized diabetic foot ulcers.
CONCLUSIONS:
Our results indicate that EPO-activated MSCs can promote the effective healing of diabetic foot ulcers. The mechanism is that EPO can change stem cells from excessive inflammation into general inflammation and improved diabetic foot ulcers inflammatory microenvironment.
Click to expand...

NewsBot · Jan 29, 2021

Topical Erythropoietin Accelerates Wound Closure in Patients with Diabetic Foot Ulcers: A Prospective, Multicenter, Single-Blind, Randomized, Controlled Trial
Saher Hamed et al
Rejuvenation Res. 2021 Jan 27

The diabetic foot ulcer (DFU) is a major disabling complication of diabetes mellitus. Growing evidence suggests topical erythropoietin (EPO) can promote wound healing. The aim of this study is to clinically assess the efficacy of a proprietary topical EPO-containing hydrogel for treating DFUs. We conducted a randomized, controlled trial in 20 patients with DFUs. After a 14-day screening period, the DFUs of 20 eligible participants who fulfilled the inclusion criteria were randomly assigned (1:1) to either a 12-week of daily treatment with topical EPO and standard-of-care (SOC) or SOC treatment alone. The DFUs were assessed weekly until week 12. The primary outcome was 75% ulcer closure or higher. After 12 weeks of treatment, 75% ulcer closure was achieved in six of the ten patients whose DFUs were treated with topical EPO and in one of the eight patients whose DFUs were treated with SOC alone. The mean area of the DFUs which were treated with topical EPO and SOC was significantly smaller than those treated with SOC alone (1.2±1.4cm2 versus 4.2±3.4cm2; p=0.023). Reepithelialization was faster in the topically EPO-treated DFUs than in the SOC-treated DFUs. There were no treatment-related adverse events. We conclude that topical EPO is a promising treatment for promoting the healing of DFUs.
Click to expand...

NewsBot The Admin that posts the news.

Admin2 Administrator Staff Member

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

Diabetic foot research in Australia

Pravibismane for diabetic foot infections

Homeopathy for Diabetic Foot Ulcers

Diabetic Foot Influencers on Twitter

Low Plasma Arginine among Patients with Diabetic Foot Ulcer

Epalrestat is effective in treating diabetic foot infection

Targeted exercises for the diabetic foot

Share This Page